Axon Enterprise, Inc $AXON Shares Sold by Cookson Peirce & Co. Inc.

Cookson Peirce & Co. Inc. lowered its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 2.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,394 shares of the biotechnology company’s stock after selling 1,082 shares during the period. Axon Enterprise comprises 1.7% of Cookson Peirce & Co. Inc.’s holdings, making the stock its 19th biggest holding. Cookson Peirce & Co. Inc.’s holdings in Axon Enterprise were worth $38,411,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in AXON. TCTC Holdings LLC increased its position in shares of Axon Enterprise by 75.0% in the first quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 24 shares in the last quarter. Bartlett & CO. Wealth Management LLC increased its position in shares of Axon Enterprise by 132.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 33 shares in the last quarter. Banque Transatlantique SA purchased a new position in shares of Axon Enterprise in the first quarter worth approximately $31,000. Catalyst Capital Advisors LLC purchased a new position in shares of Axon Enterprise in the first quarter worth approximately $32,000. Finally, Flaharty Asset Management LLC purchased a new position in shares of Axon Enterprise in the first quarter worth approximately $33,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $707.04 on Wednesday. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The company has a market cap of $55.51 billion, a PE ratio of 174.58, a PEG ratio of 26.53 and a beta of 1.41. The company’s 50-day moving average is $735.50 and its two-hundred day moving average is $720.82. Axon Enterprise, Inc has a 1 year low of $422.38 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. The company had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.Axon Enterprise’s revenue was up 32.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. Equities analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently commented on AXON. Bank of America raised their price target on shares of Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a research report on Wednesday, September 24th. Raymond James Financial reaffirmed an “outperform” rating and set a $855.00 target price (up previously from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday, October 8th. Finally, UBS Group reissued a “neutral” rating and issued a $840.00 price target (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and a consensus target price of $841.64.

Insider Buying and Selling

In other news, President Joshua Isner sold 15,919 shares of the company’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $746.26, for a total value of $11,879,712.94. Following the completion of the sale, the president directly owned 238,379 shares of the company’s stock, valued at $177,892,712.54. This represents a 6.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Brittany Bagley sold 5,000 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total value of $3,569,400.00. Following the completion of the sale, the chief financial officer directly owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. This trade represents a 5.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,932 shares of company stock worth $45,115,616 over the last quarter. Insiders own 5.70% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.